Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Securitize and Cantor Equity Partners II Business Combination Expected to Raise Approximately $400 million in Gross Proceeds and Announce Expected Closing of Business Combination and NYSE Listing